BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune-educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. Its product pipeline includes Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and for platinum resistant ovarian cancer; MVP-S +1 Keytruda that is in IIb clinical trial to treat lung cancer, bladder cancer, liver cancer, DLBCL, and ovarian cancer subpopulations; BVX-0918, a haptenized tumor cell vaccine for ovarian cancer; and DPX SurMAGE, which is in phase I clinical stage to treat the MAGE protein family member A9 in human cancers. It also develops DPX-RSV that is in phase II clinical stage for Respiratory Syncytial Virus; DPX-Flu, which is in phase I clinical stage used to treat multiple strains of influenza; DPX-Neo, which is in phase I trial used for evaluating UConn Health's proprietary neoepitopes; DPX-E7 to evaluate changes in CD8+ T cells in peripheral blood and tumor tissue and evaluate the safety in HLA-A2positive patients; and DPX-rPA anthrax vaccine. In addition, the company operates T-Cell Antigen Discovery Program. It has agreement with AP Visionaries, Inc. to develop a proprietary DPX? formulation to address the urgent need for a therapy to treat or alleviate the potentially life-threatening risk of certain food allergies, namely those triggered by exposure to peanut/tree nuts or eggs. BioVaxys Technology Corp. is headquartered in Etobicoke, Canada.